gemfibrozil (lopid) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Gemfibrozil, a fibric acid antilipemic agent similar to clofibrate, is used to treat hyperlipoproteinemia and as a second-line therapy for type IIb hypercholesterolemia. It acts to reduce triglyceride levels, reduce VLDL levels, reduce LDL levels (moderately), and increase HDL levels (moderately). Gemfibrozil increases the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis. It does so by activating Peroxisome proliferator-activated receptor-alpha (PPARα) 'transcription factor ligand', a receptor that is involved in metabolism of carbohydrates and fats, as well as adipose tissue differentiation. This increase in the synthesis of lipoprotein lipase thereby increases the clearance of triglycerides. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL. This is accompanied by a slight increase in secretion of lipids into the bile and ultimately the intestine. Gemfibrozil also inhibits the synthesis and increases the clearance of apolipoprotein B, a carrier molecule for VLDL. Gemfibrozil is most commonly sold as the brand name, Lopid. Other brand names include Jezil and Gen-Fibro.   NCATS

Chemistry

  • SMILES: CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1
  • InChIKey: HEMJJKBWTPKOJG-UHFFFAOYSA-N
  • Mol. Mass: 250.3334
  • ALogP: 3.57
  • ChEMBL Molecule:
    gemfibrozil  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.1075 - $6.6549

Australia

$0.1279
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2,2-dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure | 2,2-dimethyl-5-(2,5-xylyloxy)valeriansaeure | 2,2-dimethyl-5-(2,5-xylyloxy)valeric acid | ci-719 | decrelip | emfib | gemfibrosil | gemfibrozil | gemfibrozilo | gemfibrozilum | lopid | lopizid

Organizations (53)

Research & Development (36)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (22)

Approved Indications (4)


 

Abdominal Pain

Coronary Disease

Heart Diseases (approved 1981)

Hyperlipidemias (approved 1981)

Experimental Indications - Clinical Trial Phases 1-4 (20)


 

Alcoholism (Phase 2)

Alzheimer Disease (Early Phase 1)

Anemia (Phase 1)

Atherosclerosis (Phase 4)

Biological Availability (Phase 1)

Cardiovascular Diseases (Phase 2)

Coronary Disease (Phase 3)

Diabetes Mellitus, Type 2 (Phase 1)

Drug Interactions (Phase 1)

Healthy Volunteers (Phase 4)

Heart Diseases (Phase 2)

HIV Infections (Phase 1)

Hypertriglyceridemia (Phase 1)

Multiple Sclerosis (Phase 1)

Myocardial Ischemia (Phase 2)

Neoplasms (Phase 1)

Parkinson Disease (Phase 2)

Pharmacokinetics (Phase 1)

Smoking Cessation (Phase 2)

Tobacco Use Disorder (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 34
  • # of Trial Organizations: 36

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue